Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update
2016 Pan Pacific Lymphoma ConferenceJonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.
Related Videos
Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma
Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be s...
John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?
John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges...
Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma
Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relap...
Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
